Study	Vaccine	Timeframe postvaccination	Measure/s of effectiveness	Age groups included	Variants analysed	Study Type	Country	Data derived from
Tartof et. al. ^{†1}	BNT162b2 ^A	0.5 – 7.25	i) PCR positive ii) Hospitalisation ^B	12-15 16-44 45-64 ≥65	pre-Delta Delta	Retrospective cohort study	USA	Appendix tables 6-8
Goldberg et. al. ^{†2}	BNT162b2 ^A	1.5-6.5 months	i) PCR positive ^C ii) Severe disease ^D	16-39 40-59 ≥60	Delta	Retrospective cohort study	Israel	Table S7
Chemaitelly et. al. ^{†3}	BNT162b2	0.5-≥7 months	i) PCR positive ii) Hospitallisation (Severe disease Critical Disease And Fatal)	any	Alpha, Beta ^E , Delta	Test negative case control	Qatar	Table 2
Keehner et. al. ⁴	BNT162b2 or mRNA-1273	1-7 months	PCR positive and > 1 symptom	≥18	Delta ^F	Retrospective cohort study	USA	Calculated based on attack rates for July given in text
Andrews et. al. ⁵	BNT162b2 ChAdOx1 nCoV- 19 mRNA-1273	0.5-≥9 months	i) PCR confirmed symptomatic disease ii) Hospitalisation iii) Death	≥65 40-64	Alpha Delta	Test negative case control	England	Table 1 Table 2 Table S10 Table S11 Table S12
El Sahly et. al. ⁶	mRNA-1273	0.5-≥8 months	i) Prevention of illness ii) Prevention of severe disease	≥65	Ancestral	Randomised controlled trial	USA	Supplementary Table S30

Thomas et.	BNT162b2	0.25-≥4 months	i) Laboratory	12-15	pre-Delta	Randomised	USA	Figure 2
al. ⁷			confirmed	≥16		controlled	Argentina	
			disease (≥ 1			trial	Brazil	
			symptom)				South Africa	
							Germany	
							Turkey	
Rosenberg	BNT162b2	0-8 months	i) Laboratory	18-49	pre-Delta	Retrospective	USA	Tables 2 and 3
et. al. ⁸	mRNA-1273		confirmed	50-64	Delta	cohort study		
			disease	≥65				
			ii) Hospitalisation					
Andrews et.	BNT162b2	0.5-~25 months	i) PCR confirmed	≥18	Delta	Test negative	England	Table 3
al. ^{9,10}	ChAdOx1 nCoV-		symptomatic		Omicron	case control		
	19		disease					
	mRNA-1273		ii) Hospitalisation					
Ferdinands	mRNA vaccines	0.5-25 months	i) PCR confirmed	≥18	Delta	Test negative	USA	Table 2
et. al. ¹¹			hospital		Omicron	case control		
			presentation					
			ii) PCR confirmed					
			hospital					
			admission					
Bruxvoort	mRNA-1273	0.5-6 months	PCR confirmed	≥18	Delta	Test negative	USA	Extracted from Figure 2
et. al. ^{†12}			infection			case control		
Poukka et.	mRNA vaccines	0-8 months	i) Laboratory	16-69	pre-Delta	Retrospective	Finland	Supplementary table 2 and 3
al. ^{†13}	ChAdOx1 nCoV-		confirmed		Delta	cohort study		
	19		infection					
			ii) Hospitalisation					
Tseng et.	mRNA-1273	0.5-25 months	i) Infection ii)	≥18	Delta	Test negative	USA	Table 2
al. ¹⁴			Hospitalisation		Omicron	case control		
Skowronski	BNT162b2	0.5-11.5 months	i) PCR positive	≥18	Delta	Test negative	Canada	Supplementary table 14 and
et. al. ^{†15}			infection			case control		15

	ChAdOx1-		ii) hospitalisation					
	nCoV-19							
	mRNA-1273							
Thompson et. al. ¹⁶	mRNA vaccines	0.5-25 months	Hospitalisation	≥18	Delta Omicron	Test negative case control	USA	Table 2

Supplementary Table 1 Data sources for Efficacy Data

^A Fully vaccinated = 7 days + post second dose

^B Hospitalisation data was not split by variant

^c PCR positive efficacy included for ages >16 years

^D Severe disease efficacy included for ages >40 years

^E Effectiveness against Beta infections were not included in this analysis

^F Infections were >95% Delta in timeframe analysed

[†] Denotes studies that included efficacy against confirmed infection without reporting on symptoms. These data were not included in the final analysis.

References:

- 1. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021; **398**(10309): 1407-16.
- 2. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med 2021; **385**(24): e85.
- 3. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021; **385**(24): e83.
- 4. Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. *N Engl J Med* 2021; **385**(14): 1330-2.
- 5. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. *N Engl J Med* 2022; **386**(4): 340-50.
- 6. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med* 2021; **385**(19): 1774-85.
- 7. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021; **385**(19): 1761-73.
- 8. Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 Vaccine Effectiveness in New York State. N Engl J Med 2022; **386**(2): 116-27.
- 9. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
- 10. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. *medrxiv* 2021: doi:10.1101/2021.12.14.21267615.
- 11. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(7): 255-63.
- 12. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. *BMJ* 2021; **375**: e068848.
- 13. Poukka E, Baum U, Palmu AA, et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 October 2021. *Vaccine* 2022; **40**(5): 701-5.
- 14. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med* 2022; **28**(5): 1063-71.
- 15. Skowronski DM, Febriani Y, Ouakki M, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. *medrxiv* 2021.
- 16. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4): 139-45.